Cerclage Technique for Repairing Large Circular Defects of the Trunk: Two‐Staged Excision of a Plexiform Neurofibroma

Department of Dermatology, Western University College of Osteopathic Medicine/Pacific Hospital, Long Beach, California 90806, USA.
Dermatologic Surgery (Impact Factor: 2.11). 08/2008; 34(7):939-43. DOI: 10.1111/j.1524-4725.2008.34181.x
Source: PubMed

ABSTRACT The authors have indicated no significant interest with commercial supporters.

11 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurofibromatosis is characterized by multiple café-au-lait spots and cutaneous neurofibromas. Laryngeal involvement in neurofibromatosis is rare and is usually manifested by obstructive airway symptoms. We encountered a 1 year 8-month-old girl who was a victim of neurofibromatosis with the presentation of stridor. Fiberoptic laryngoscopy revealed a round smooth mass over the right aryepiglottic fold which prolapsed into the larynx during inspiration. Carbon dioxide laser excision was performed and histopathologic examination revealed a plexiform neurofibroma. The patient had regular follow up for almost 4 years. Even though there seemed to be a recurrence, she remained symptom free.
    International Journal of Pediatric Otorhinolaryngology 10/2002; 65(2):167-70. DOI:10.1016/S0165-5876(02)00151-9 · 1.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This pediatric phase I trial of tipifarnib determined the maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of tipifarnib in children with refractory solid tumors and neurofibromatosis type 1 (NF1) -related plexiform neurofibromas. Tipifarnib was administered twice daily for 21 days, repeated every 28 days starting at 150 mg/m2/dose (n = 4), with escalations to 200 (n = 12), 275 (n = 12), and 375 (n = 6) mg/m2/dose. The MTD was also evaluated on a chronic continuous dosing schedule (n = 6). Pharmacokinetic sampling was performed for 36 hours after the first dose and peripheral-blood mononuclear cells (PBMCs) were collected at baseline and steady state for determination of farnesyl protein transferase (FTase) activity and HDJ-2 farnesylation. Twenty-three solid tumor and 17 NF1 patients were assessable for toxicity. The MTD was 200 mg/m2/dose, and dose-limiting toxicities on cycle 1 were myelosuppression, rash, nausea, vomiting, and diarrhea. The 200 mg/m2/dose was also tolerable on the continuous dosing schedule. Cumulative toxicity was not observed in the 17 NF1 patients who received a median of 10 cycles (range, 1 to 32 cycles). The plasma pharmacokinetics of tipifarnib were highly variable but not age dependent. At steady state on 200 mg/m2/dose, FTase activity was 30% compared with baseline, and farnesylation of HDJ-2 was inhibited in PBMCs. Oral tipifarnib is well tolerated in children receiving the drug twice daily for 21 days and a continuous dosing schedule at 200 mg/m2/dose, which is equivalent to the MTD in adults. The pharmacokinetic profile of tipifarnib in children is similar to that in adults, and at the MTD, FTase is inhibited in PBMC in vivo.
    Journal of Clinical Oncology 02/2006; 24(3):507-16. DOI:10.1200/JCO.2005.03.8638 · 18.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mohs surgical defects in 26 patients were reconstructed utilizing a purse-string suture and a full-thickness graft. The placement of the purse-string suture decreased the surface area of the wound an average of 53%. A full-thickness graft was then placed in the remaining defect. This technique enabled us to repair large wounds of the facial region with a relatively small full-thickness graft. There were no complications in our series. The resultant areas were cosmetically acceptable and resistant to trauma.
    The Journal of dermatologic surgery and oncology 10/1992; 18(9):812-6. DOI:10.1111/j.1524-4725.1992.tb03039.x
Show more

Preview (3 Sources)

11 Reads
Available from